Seagen (SGEN) Tops Q2 EPS by 38c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seagen Reports Second Quarter 2022 Financial Results
July 28, 2022 4:02 PM EDT-Total Revenues of $498 Million in 2Q22, Including Net Product Sales of $432 Million-
-Announced Positive Topline Results for PADCEV with KEYTRUDA as First-Line Treatment for Advanced Urothelial Cancer-
-Presented Positive Results from Pivotal MOUNTAINEER Trial Demonstrating Antitumor Activity of TUKYSA in Combination with Trastuzumab for Previously Treated HER2-Positive Metastatic Colorectal Cancer-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq: SGEN) reported financial results today for the second quarter ended June 30, 2022. The Company also highlighted PADCEV®... More
